title: [Suppressive effects of GTW treatment on mesangial lesions in experimental irreversible glomerulosclerosis].
abstract: OBJECTIVE
  To examine suppressive effects of multi-glycoside of Tripterygium wilfordii Hook. f. (GTW)on mesangial injury induced by two-injecti on of anti-Thy1. 1 monoclonal antibody(mAb) 1-22-3 in vitro.
  
  
  METHODS
  We established the irreversible model of glomerulosclerosis with anti-Thy1. 1 mAb 1-22-3. After 42 days of oral treatment with GTW (50 mg x kg(-1) BW)and vehicle (distilled water), to observe effects of GTW on proteinuria, renal function, mesangial morphological change, and mRNA expressions of collagen type I and TGF-beta by light microscope (LM), immunofluorescence (IF), and Reverse Transcription Polymerase Chain Reaction (RT-PCR).
  
  
  RESULTS
  GTW ameliorated proteinuria (from day24 to day 42) and mesangial proliferation [total cell number, GTW group 65.67+/-3.43 vs. control group 87.02+/-2.41, P < 0.05; matrix expansion, GTW group 1.20+/-0.06 vs. control group 2.77+/-0.23, P < 0.05; alpha-smooth muscle actin(alpha-SMA) expression, GTW group 1.75+/-0.33 vs. control group 2.62+/-0.15, P < 0.05; collagen type I expression, GTW group 1.68+/-0.31 vs. control group 2.06+/-0.24, P < 0.05], moreover, significantly reduced the glomerular expression of mRNA for collagen type 1(53.5% to the control group, P < 0.05)and TGF-beta(14.7% to the control group, P < 0.05)on day 42day.
  
  
  CONCLUSIONS
  GTW can not only decrease proteinuria, but also ameliorate mesangial alterations probably by the reduction of cytokines. GTW may be a promising agent for the prevention of progressive and irreversible glomerulosclerosis.
authors.affiliation: The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, China. wyg68918@sina.com
authors.forename: Yi-gang
authors.initials: YG
authors.lastname: Wan
authors.forename: Wei
authors.initials: W
authors.lastname: Sun
authors.forename: Fujio
authors.initials: F
authors.lastname: Shmizu
authors.forename: Liu-bao
authors.initials: LB
authors.lastname: Gu
authors.forename: Koichi
authors.initials: K
authors.lastname: Suziki
authors.forename: Tamaki
authors.initials: T
authors.lastname: Karasawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawachi
mesh_terms: D000185:Actinin / Q000378:metabolism; D000818:Animals; D024042:Collagen Type I / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D005920:Glomerular Mesangium / Q000378:metabolism / Q000473:pathology*; D015432:Glomerulonephritis, Membranoproliferative / Q000378:metabolism* / Q000473:pathology; D006027:Glycosides / Q000302:isolation & purification / Q000494:pharmacology*; D010946:Plants, Medicinal / Q000737:chemistry; D011507:Proteinuria / Q000188:drug therapy; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000235:genetics; D029757:Tripterygium / Q000737:chemistry
chemical_list: D024042:Collagen Type I; D006027:Glycosides; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; D000185:Actinin